ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC)
BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - January 09, 2017) - Oryzon Genomics (MAD: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical …